Minerva Neurosciences (NERV) Other Non Operating Income (2013 - 2026)
Minerva Neurosciences (NERV) posted Other Non Operating Income of -$1804.0 for Q1 2026, up 91.34% on a QoQ basis from -$20823.0 in Q4 2025, and up 78.46% year-over-year from -$1010.9 in Q1 2025.
Minerva Neurosciences (NERV) Other Non Operating Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Other Non Operating Income history runs 14 years deep, the most recent figure standing at -$1804.0 for Q1 2026.
- Quarterly Other Non Operating Income rose 78.46% year-over-year to -$1804.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49983.0 (down 216.45% YoY) and the FY2025 annual result came in at -$56555.0, down 2836.4% from the prior year.
- Other Non Operating Income was -$1804.0 for Q1 2026 at Minerva Neurosciences, up from -$20823.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $10383.0 in Q4 2024 and bottomed at -$27606.0 in Q4 2022.
- A 5-year average of -$7544.8 and a median of -$6246.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 567.13% — and 2024, when it jumped 163.24%.
- Minerva Neurosciences' Other Non Operating Income stood at -$27606.0 in 2022, then jumped by 30.28% to -$19247.0 in 2023, then soared by 153.95% to $10383.0 in 2024, then tumbled by 300.55% to -$20823.0 in 2025, then jumped by 91.34% to -$1804.0 in 2026.
- Business Quant data shows NERV's Other Non Operating Income at -$1804.0 in Q1 2026, -$20823.0 in Q4 2025, and -$6246.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,804.00 |
| Dec 31, 2025 | -20,823.00 |
| Sep 30, 2025 | -6,246.00 |
| Jun 30, 2025 | -21,110.00 |
| Mar 31, 2025 | -8,376.00 |
| Dec 31, 2024 | 10,383.00 |
| Sep 30, 2024 | -13,108.00 |
| Jun 30, 2024 | -4,694.00 |
| Mar 31, 2024 | 5,493.00 |
| Dec 31, 2023 | -19,247.00 |
| Sep 30, 2023 | -5,096.00 |
| Jun 30, 2023 | -7,206.00 |
| Mar 31, 2023 | -8,686.00 |
| Dec 31, 2022 | -27,606.00 |
| Sep 30, 2022 | 2,063.00 |
| Jun 30, 2022 | 1,596.00 |
| Mar 31, 2022 | -3,794.00 |
| Dec 31, 2021 | -4,138.00 |
| Sep 30, 2021 | -4,855.00 |
| Jun 30, 2021 | -18,997.00 |